Want to see IGC full AI Analyst Report?
IGC Stock Chart & Stats
$0.30
>-$0.01(-2.38%)
At close: 4:00 PM EST
$0.30
>-$0.01(-2.38%)
Day’s Range― - ―
52-Week Range$0.24 - $0.50
Previous CloseN/A
Volume646.33K
Average Volume (3M)715.71K
Market Cap
$26.72M
Enterprise Value$28.31M
Total Cash (Recent Filing)$235.00K
Total Debt (Recent Filing)$933.00K
Price to Earnings (P/E)―
Beta0.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding100,091,320
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue23.87
Enterprise Value/Gross Profit80.44
Enterprise Value/Ebitda-4.59
Forecast
1Y Price Target
$5.50Price Target Upside1733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtHaving essentially no debt materially lowers fixed financing obligations and interest risk, preserving runway flexibility to fund clinical programs. Low leverage supports strategic optionality for partnerships or non-dilutive financings and reduces solvency risk during multi-year R&D cycles.
Clinical Trial Execution: CALMA Phase 2 EnrollmentCompleting target enrollment is a durable operational milestone that reduces enrollment and timeline risk, enabling a timely topline readout. Strong trial execution improves the credibility of data quality, supports regulatory engagement, and de-risks the development pathway over the coming months.
Proprietary Data Platform: Agentic Harmonization Assistant (AHA)Launching AHA represents a structural expansion beyond single-drug R&D: it can improve internal R&D efficiency and become a recurring data-services asset. Demonstrated 90% time reduction in harmonization suggests competitive edge in preparing AI-ready datasets and partnership potential with institutions.
Bears Say
Severe Revenue Contraction And Deep LossesThe combination of collapsing revenue and outsized negative margins indicates the core business is not generating scalable commercial economics. Sustained profitability will rely on successful trial outcomes or new revenue lines; absent that, operating losses will continue to pressure capital and strategic options.
Ongoing Cash Burn And Negative Operating Cash FlowNegative operating and free cash flow means the company cannot self-fund development and must access external capital. Persistent burn creates dilution or covenant risk, constrains multi-year R&D planning, and places emphasis on financing availability rather than organic cash generation.
Eroding Shareholders' Equity / Shrinking Capital CushionA sharply reduced equity base limits the firm's ability to absorb setbacks and reduces financial resilience. With a smaller capital cushion, management faces greater pressure to raise funds, potentially under dilutive terms, which can hamper long-term strategic flexibility and investor confidence.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.24 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $26.72M.
When is IGC Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IGC Pharma’s earnings last quarter?
Currently, no data Available
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 100,091,320 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC Stock 12 Month Forecast
Average Price Target
$5.50
▲(1733.33% Upside)
Technical Analysis
Ownership Overview
13.06% Insiders
1.37% Mutual Funds
<0.01% Other Institutional Investors
84.07% Public Companies and
Individual Investors